Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

Autor: Ravandi, Farhad *, Assi, Rita, Daver, Naval, Benton, Christopher B, Kadia, Tapan, Thompson, Philip A, Borthakur, Gautam, Alvarado, Yesid, Jabbour, Elias J, Konopleva, Marina, Takahashi, Koichi, Kornblau, Steven, DiNardo, Courtney D, Estrov, Zeev, Flores, Wilmer, Basu, Sreyashi, Allison, James, Sharma, Padmanee, Pierce, Sherry, Pike, Allison, Cortes, Jorge E, Garcia-Manero, Guillermo, Kantarjian, Hagop M
Zdroj: In The Lancet Haematology September 2019 6(9):e480-e488
Databáze: ScienceDirect